Impact of Immunoglobulin Therapy on Infections in Multiple Myeloma Patients
Author Information
Author(s): Khalafallah Alhossain, Maiwald Matthias, Cox Amanda, Burns Denise, Bates Gerald, Hannan Terry, Seaton David, Fernandopulle Bernadene, Meagher Damien, Brain Terry
Primary Institution: Launceston General Hospital
Hypothesis
Does intravenous immunoglobulin therapy reduce the rate of infections in multiple myeloma patients undergoing treatment?
Conclusion
Intravenous immunoglobulin therapy significantly reduces the rate of infections in multiple myeloma patients treated with immunomodulatory agents or undergoing autologous stem cell transplantation.
Supporting Evidence
- Patients receiving IVIG therapy showed a significant decline in infection rates.
- The median residual IgG level improved significantly after IVIG therapy.
- No recorded admissions for severe infections were noted after IVIG therapy.
Takeaway
This study found that giving special antibodies to multiple myeloma patients helps them get fewer infections while they are being treated.
Methodology
Retrospective analysis of 47 multiple myeloma patients receiving immunomodulatory therapy and IVIG treatment.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and may not account for all variables affecting infection rates.
Participant Demographics
Median age of participants was 64 years, with a female-to-male ratio of 18:29.
Statistical Information
P-Value
p=0.03
Confidence Interval
95% CI 0.09 to 0.19
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website